An alliance of for-profit companies and academia is supporting the GenomeAsia 100K project that seeks to do whole-genome sequencing on 100,000 people in South Asia. Now, startup MedGenome has said it will kick in $10 million toward the effort to become a founding member.
Coming just a few days after the U.S. Pharmaceutical Research and Manufacturers of America called laws in India governing intellectual property "weak," a report out from the subcontinent says the Indian Pharmaceutical Alliance is making moves to assuage concerns from the U.S. Trade Representative over its IP laws.
The U.S. Food and Drug Administration rejected more than 13,000 products made in India in the 5 years between 2010 and 2015, according to FDA data cited in an Economic Times report, and rejected slightly more than 15,000 products made in China.
The Pharmaceutical Research and Manufacturers of America (PhRMA), one of the top bodies representing American pharmaceutical and biotechnology companies, said in its annual report that India's intellectual property rights protection is weak and the group added India to its "priority watch list."
Indian doctors recently saved the life of a 30-year-old woman by instructing an unspecialized doctor about chest compressions over Internet-enabled video. The country's private hospital chains such as Fortis and Apollo plan to expand the number of so-called eICU beds by about 20% a year, from about 3,000 beds right now.
The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.
Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.
GlaxoSmithKline's CEO Andrew Witty, who has been accused by major investors of "not doing a very good job" and is in the crosshairs of hedge funds, said in a recent interview in India that it is "difficult to understand how the company is doing because so much has changed."
Mumbai-based Sun Pharmaceutical Industries met an in-house deadline of Feb. 1 to launch sales of generic Gleevec/Glivec (imatinib) in the U.S. that included a savings card program to cut the co-payment out-of-pocket costs for the cancer treatment with certain pharmacies.
It has been another tough week for some of India's troubled drugmakers. Wockhardt, which has two plants banned by the FDA, saw its hopes stymied for getting export approval for a different facility that it had hoped could help it recoup some of its lost U.S. revenues. And India's Ipca Laboratories, which has three plants on the import alert list, said Monday it has now gotten a warning letter for the facilities.